|2.||Polycystic Ovary Syndrome (Syndrome, Stein-Leventhal)
|4.||Spontaneous Abortion (Miscarriage)
|1.||Pellicer, Antonio: 18 articles (01/2015 - 11/2002)|
|2.||Orvieto, Raoul: 12 articles (11/2015 - 10/2004)|
|3.||Simón, Carlos: 11 articles (01/2015 - 11/2002)|
|4.||Gómez, Raúl: 9 articles (01/2015 - 11/2002)|
|5.||Kol, Shahar: 8 articles (11/2015 - 05/2003)|
|6.||Humaidan, Peter: 8 articles (06/2015 - 07/2010)|
|7.||Diedrich, K: 8 articles (01/2009 - 07/2000)|
|8.||Yang, Yu-Shih: 7 articles (03/2013 - 07/2003)|
|9.||Devroey, P: 7 articles (11/2012 - 07/2000)|
|10.||Pellicer, A: 7 articles (10/2009 - 05/2002)|
|1.||Gonadotropin-Releasing Hormone (GnRH)FDA Link
05/01/2014 - "Gonadotropin releasing hormone agonist triggers are very effective in eliminating early-onset ovarian hyperstimulation syndrome (OHSS). "
02/01/2003 - "As for GnRHa, GnRH antagonists have been proven effective to prevent the LH surge and to reduce the incidence of severe ovarian hyperstimulation syndrome in controlled ovarian stimulation cycles."
04/01/2015 - "However, the short duration of the LH surge with the GnRH-a trigger (approximately 34 hours) has been shown to be beneficial for preventing ovarian hyperstimulation syndrome in GnRH antagonist in vitro fertilization (IVF) cycles when compared with the prolonged elevation of hCG (≥6 days) after exposure to an hCG bolus. "
01/01/2015 - "To determine if the GnRH antagonist protocol is effective in preventing ovarian hyperstimulation syndrome (OHSS) in potentially high responders. "
01/01/2013 - "To evaluate, whether Gonadotropin-releasing hormone-agonist (GnRH-agonist or GnRH-ag) trigger in patients undergoing the ultrashort GnRH-ag/GnRH-antagonist (GnRH-ant) protocol is as effective as in patients at high risk to develop severe ovarian hyperstimulation syndrome (OHSS), who undergo the multidose GnRH-ant protocol. "
11/01/2013 - "The use of cabergoline and coasting are both effective in reducing the risk of ovarian hyperstimulation syndrome (OHSS). "
03/01/2012 - "To compare the efficacy of cabergoline (Cb2) and intravenous human albumin (HA) in the prevention of ovarian hyperstimulation syndrome. "
10/01/2015 - "Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: A randomized controlled study."
03/01/2014 - "Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials."
10/01/2013 - "Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: A clinical trial study."
|3.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
04/01/2010 - "Although mechanistic evidence is not provided, the pivotal role of VEGF in ovarian hyperstimulation syndrome prompts investigation of TZDs as a novel treatment for this condition."
03/01/2004 - "The aim of this study was to assess the effect of withholding gonadotrophins (coasting) during controlled ovarian stimulation (COS) on individual follicle concentrations of follicular fluid vascular endothelial growth factor (VEGF) in women at high risk of developing ovarian hyperstimulation syndrome (OHSS). "
11/01/2001 - "[Preliminary study on the role of vascular endothelial growth factor in pathogenesis of ovarian hyperstimulation syndrome]."
01/01/2015 - "We sought to determine the effects of D2 signaling on VEGF transcription and translation in LGCs, with the expectation of identifying potential D2-ag-based therapies for ovarian hyperstimulation syndrome (OHSS). "
01/01/2015 - "Serum VEGF and AT-II were possible contributors to an increased risk of developing ovarian hyperstimulation syndrome (OHSS) in patients with typical PCOS during the early follicular phase (3 hours) after ovarian stimulation ( NCT02265861)."
01/01/2015 - "The aim of this study was to evaluate the efficacy of ovarian steroid hormone suppression in luteal phase after oocyte retrieval for preventing severe ovarian hyperstimulation syndrome (OHSS) in high-risk patients with embryo cryopreservation. "
12/01/2012 - "The combined use of a gonadotrophin-releasing hormone antagonist protocol with gonadotrophin-releasing hormone agonist triggering and oocyte and embryo freezing has considerable promise in preventing ovarian hyperstimulation syndrome. "
01/01/2015 - "The aim of this study is to investigate the potential role of attenuated anti-Müllerian hormone signaling in the pathogenesis of ovarian hyperstimulation syndrome (OHSS). "
09/01/1991 - "In this study, we report an alternative method of management of patients at a potential risk of ovarian hyperstimulation syndrome (OHSS) in an in-vitro fertilization (IVF) programme, by the use of gonadotrophin releasing hormone analogue (GnRHa). "
01/01/2015 - "Currently, IVM is reserved for carefully selected patients at risk for ovarian hyperstimulation syndrome and for those with contraindications to hormone administration. "
01/01/2015 - "It is as effective as gonadotropins in terms of pregnancy and live birth rates, but without the risks of ovarian hyperstimulation syndrome and multiple pregnancies. "
11/01/2014 - "During assisted reproductive techniques, AMH assay is very useful choosing the ovarian stimulation protocol and the dose of gonadotropins to begin with, in order to limit the risks of ovarian hyperstimulation syndrome or on the other hand, cancellation of cycles due to poor ovarian response. "
07/01/2003 - "To compare the efficacy of coasting to prevent ovarian hyperstimulation syndrome (OHSS) with i.v. albumin and to determine if different timing of gonadotropin coasting would affect the IVF outcomes. "
04/01/2011 - "The subject of the study is to compare the clinical characteristics of recombinant gonadotropins versus urinary ones focused on the daily dose of FSH achieving FSH threshold and the risk of multifollicular development in ovulation induction before intrauterine insemination, number of follicles and oocytes, the risk of ovarian hyperstimulation syndrome (OHSS), total consumption of FSH, cost effectiveness and expected pregnancy rate during in vitro fertilization technique. "
03/01/2011 - "Studies have shown that ovulation and pregnancy rates are comparable between ovulation induction with gonadotropins and LOD, but LOD avoids the risks of multiple pregnancy and ovarian hyperstimulation syndrome. "
01/01/2012 - "hCG and progesterone produce the best results and are comparable or at best a slight edge to hCG but the latter is associated with too high a risk for ovarian hyperstimulation syndrome. "
05/01/2001 - "Since progesterone is as effective as hCG for luteal phase support but provides a higher safety with regard to ovarian hyperstimulation syndromes, and vaginal progesterone is as effective as intramuscular progesterone, vaginal progesterone should be the standard choice for luteal phase support. "
01/01/2011 - "There was a significantly higher risk of ovarian hyperstimulation syndrome (OHSS) when hCG was used (Peto OR 3.62, 95% CI 1.85 to 7.06).There were eight studies (875 women) in the second comparison, progesterone versus placebo or no treatment. "
01/01/2009 - "While ovarian hyperstimulation syndrome is associated with human chorionic gonadotrophin (HCG), studies suggest that exogenous progesterone provides necessary luteal support in patients undergoing IVF. "
01/01/2000 - "This study was designed to compare the effectiveness of intramuscular progesterone with that of intravenous albumin in the prevention of ovarian hyperstimulation syndrome (OHSS). "
|7.||Hetastarch (Pentastarch)FDA Link
01/01/2001 - "10% hydroxyethyl starch for plasma expansion in the treatment of severe ovarian hyperstimulation syndrome. "
03/01/2003 - "Comparative efficacy of hydroxyethyl starch and haemaccel in the treatment of severe ovarian hyperstimulation syndrome."
06/01/2002 - "Efficacy of hydroxyethyl starch and haemaccel for the treatment of severe ovarian hyperstimulation syndrome."
01/01/2011 - "To review the effectiveness and safety of administration of intravenous fluids such as albumin, hydroxyethyl starch, Haemaccel® and dextran in the prevention of severe ovarian hyperstimulation syndrome (OHSS) in IVF or ICSI treatment cycles. "
10/01/2013 - "Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch."
|8.||Clomiphene (Clomifene)FDA LinkGeneric
01/01/2014 - "Scleroderma renal crisis and ovarian hyperstimulation syndrome related to the use of clomiphene in a patient with scleroderma."
01/01/2009 - "However, because of the physical and emotional burdens on the patient, and the possibility of multiple pregnancy and ovarian hyperstimulation syndrome, re-treatment with clomiphene citrate was then selected. "
01/01/2009 - "Frequent use of ovulation inductors (Clomiphene Gonadotrop(h)in) is accompanied by ovarian hyperstimulation syndrome. "
01/01/2009 - "[Clomiphene, ovarian hyperstimulation syndrome and pregnancy]."
09/01/2001 - "Ovarian hyperstimulation syndrome associated with clomiphene citrate."
|10.||Chorionic Gonadotropin (Human Chorionic Gonadotropin)FDA LinkGeneric
04/01/2011 - "The aim of the study is to decrease the risk of the development of ovarian hyperstimulation syndrome (OHSS) at high response donors by the replacement of Pregnyl 10 000 IU i.m. "
02/01/2016 - "Human chorionic gonadotropin (hCG) is a known trigger of ovarian hyperstimulation syndrome (OHSS), a potentially life-threatening complication of assisted reproduction. "
11/01/2014 - "(I) 5. There is no clear published evidence that lowering the human chorionic gonadotropin dose will result in a decrease in the rate of ovarian hyperstimulation syndrome. "
04/01/2014 - "Relationship between human chorionic gonadotropin serum levels and the risk of ovarian hyperstimulation syndrome."
11/01/2011 - "Ovarian hyperstimulation syndrome (OHSS) incidentally occurs in controlled ovarian stimulation protocols and is associated with human chorionic gonadotropin (hCG) administration. "
|1.||Autologous Blood Transfusion
11/01/1992 - "Autotransfusion of the ascitic fluid in the treatment of severe ovarian hyperstimulation syndrome."
08/01/1998 - "[Integral treatment of severe ovarian hyperstimulation syndrome by means of autotransfusion of ascitic fluid and intravenous infusion of albumin]."
11/01/2012 - "Autotransfusion of protein in concentrated ascites for the treatment of severe ovarian hyperstimulation syndrome was effective and safe."
01/01/2000 - "We investigated prospectively the clinical efficacy of a newly developed continuous autotransfusion system of ascites (CATSA) without protein supplement in patients with severe ovarian hyperstimulation syndrome (OHSS). "
|2.||Laser Therapy (Surgery, Laser)
07/01/1995 - "Our purpose was to examine the efficacy of laser vaporization of the ovarian surface in polycystic ovary disease to reduce repeated ovarian hyperstimulation syndrome and thereby improve pregnancy outcome. "
07/01/1995 - "Laser vaporization is promising for the prevention of ovarian hyperstimulation syndrome and improving pregnancy outcome in patients with polycystic ovary disease who have previously had ovarian hyperstimulation syndrome."
03/01/1993 - "These results suggest that ovarian laser vaporization is very useful when clomiphene citrate fails in PCOD, and has no risk of ovarian hyperstimulation syndrome or multiple gestation, which is frequently observed in ovulation induction with drugs. "
|5.||Induced Abortion (Induced Abortions)
03/01/2011 - "Pregnancy rates and the incidence of ovarian hyperstimulation syndrome (OHSS) were analyzed in all five studies, abortion rates were analyzed on three. "
04/01/2015 - "The number of retrieved oocytes, fertilization rate, cleavage rate, high quality embryo rate, ovarian hyperstimulation syndrome (OHSS) incidence rate, cycle cancellation rate, clinical pregnancy rate, early abortion rate, Gn dosage and administration duration, and the correlation between the high quality embryo rate and SOF level were determined. "
03/01/2006 - "The outcomes assessed were clinical pregnancy per randomized patient; number of oocytes retrieved; proportion of metaphase II oocytes; fertilization rate; embryo quality score; first trimester abortion rate; ovarian hyperstimulation syndrome (OHSS) incidence. "
09/01/1994 - "Pregnancy and abortion rates and the rate of ovarian hyperstimulation syndrome (OHSS). "
02/01/2012 - "Secondary outcomes were clinical pregnancy rate (CPR), multiple pregnancy rate (MPR), ovarian hyperstimulation syndrome (OHSS), abortion rates, and cycle demographics. "